PCN107 Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.244
https://www.valueinhealthjournal.com/article/S1098-3015(20)32500-6/fulltext
Title :
PCN107 Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32500-6&doi=10.1016/j.jval.2020.08.244
First page :
Section Title :
Open access? :
No
Section Order :
10196